TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Leuven (BELGIUM) – May 4, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, is honoured to announce that the positive 52-week results from its Cx601 ADMIRE-CD Phase III clinical trial for the treatment of complex perianal fistulas in patients with Crohn`s disease will be presented at the 2017 Digestive Disease Week (DDW) annual meeting taking place from May 6-9 in Chicago, IL, USA.